Phase 2 trial in 43 adults with a primary or first recurrent C difficile infection: clinical cure was 93% with CRS3123 200 mg, 100% with 400 mg and 93% with vancomycin; recurrence by day 40 was 0%, 7% and 23%, with mild-to-moderate adverse events.
RCTn = 43
Louie et al. Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study